tbuckley/cabot-search huggingface dataset:
Exploring Dietary Patterns And The Distribution Of Atopic Dermatitis In A Birth Cohort Of A Metropolitan Area In Germany
Authors: Lennard Merdha, Lea Schmidt, Hanna Hufnagel, Hannah Wecker, Linda Tizek, Maximilian Schielein, Stefanie Ziehfreund, Tilo Biedermann, Alexander Zink
Journal: Journal of Allergy and Clinical Immunology (2022)
Epidemiology of prurigo nodularis in England: a retrospective database analysis
Authors: Christopher Ll. Morgan, Melissa Thomas, Sonja Ständer, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sylvie Gabriel, Craig J. Currie, Jorge Puelles
Journal: British Journal of Dermatology (2022)

Prurigo nodularis is a debilitating skin condition that is classified as rare by the Genetic and Rare Diseases Information Center (GARD) and the National Organization for Rare Diseases (NORD). There are currently no estimates of the prevalence of prurigo nodularis in England.We aimed to address this data gap by describing the epidemiology of prurigo nodularis in a representative dataset derived from the English National Health Service.The study utilized data from the Clinical Practice Research Datalink linked to Hospital Episode Statistics inpatient data. Patients with a diagnosis of prurigo nodularis were selected by clinical code in the primary care or inpatient datasets. Case definition was based on a minimum of two distinct diagnoses to maximize specificity. Point prevalence was calculated for the midpoint of 2018 and incidence rates from 2008 to 2018 were presented. For those classified as incident cases, demographic and clinical characteristics were reported. In sensitivity analyses the case definition was modified to relax the multiple diagnosis criteria and to restrict cases to those diagnosed within a maximum of 4 or 10 years of the midpoint prevalence date.Overall, 11 656 patients within the dataset had at least one prurigo nodularis diagnosis. Following application of the relevant inclusion criteria, 2743 patients formed the point prevalent cohort; the estimated prevalence was 3·27 patients per 10 000 population [95% confidence interval (CI) 3·15-3·40]. In sensitivity analyses the estimated prevalence ranged from 2·24 (95% CI 2·14-2·34) to 6·98 (95% CI 6·80-7·16). Incidence over the study period was 2·88 per 100 000 patient-years. Comorbidity was relatively high in this population, notably for atopic dermatitis (52·2%), depression (41·1%) and anxiety (35·4%).This study supports the NORD/GARD classification of prurigo nodularis as a rare disease with a prevalence of 3·27 patients per 10 000 population, which equates to 18 471 patients living with the disease in England in 2018. The relatively high prevalence of comorbidity observed for these patients may increase the complexity of management.
Ketamine for suicidal ideation
Authors: Riccardo De Giorgi
Journal: BMJ (2022)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Ketamine for suicidal ideation Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Assessment of Changes in Diversity in Dermatology Clinical Trials Between 2010-2015 and 2015-2020
Authors: Vivien Chen, Shifa Akhtar, Caiwei Zheng, Vignesh Kumaresan, Keyvan Nouri
Journal: JAMA Dermatology (2022)

Although there have been increased efforts in dermatologic research to improve representation of patient sex, race, and ethnicity, there are limited data evaluating resulting changes.To characterize the diversity of participants in dermatologic clinical trials conducted in the US published from 2015 to 2020 pertaining to common dermatologic conditions affecting all patient demographic categories compared with findings from 2010-2015.A systematic literature review through the PubMed database was conducted for randomized clinical trials published between July 1, 2015, and July 1, 2020, using keywords alopecia areata, acne, atopic dermatitis, lichen planus, psoriasis, seborrheic dermatitis, and vitiligo. Data collected included distribution of participant demographic characteristics, funding source, and journal type. Reflecting US Census data, studies were defined as unrepresentative of race and ethnicity if they included less than 20% ethnically or racially diverse participants or unrepresentative of sex if they included less than 45% women. Python was used for statistical analysis by χ2 tests or Fisher exact tests.A total of 392 randomized clinical trials were included. In comparison with the period from 2010-2015, the reporting rate for race and ethnicity in US studies has increased from 59.8% to 71.9% (P = .05). However, the proportion of reporting articles including at least 20% non-White representation remains unchanged at 38.1% with 37 of 97 reporting randomized clinical trials in 2010-2015 and 53 of 139 reporting randomized clinical trials in 2015-2020 (P = .99). Psoriasis studies included the least diversity, with 12.1% of studies recording at least 20% non-White participants and 29.5% of studies recording at least 45% female participants.The findings of this systematic review suggest that reporting racial and ethnic data since 2010-2015 has become more transparent. However, inclusion of representative patient populations may still be considered inadequate, particularly in psoriasis studies. Diversity in clinical trials is important for representation of the affected patient populations, and additional efforts are warranted in support of this endeavor.
Genetic Ancestry and Childhood Acute Lymphoblastic Leukemia Subtypes and Outcomes in the Genomic Era
Authors: Karen R. Rabin
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
QUERIES AND MINOR NOTES
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial
Authors: Nikolaos Perakakis, Bhanu Kalra, Angeliki M. Angelidi, Ajay Kumar, Anna Gavrieli, Mary Yannakoulia, Christos S. Mantzoros
Journal: Metabolism (2022)
Psychopathy: Current Knowledge and Future Directions
Authors: Christopher J. Patrick
Journal: Annual Review of Clinical Psychology (2022)

Research on psychopathy has progressed considerably in recent years against the backdrop of important advances in the broader field of clinical psychological science. My major aim in this review is to encourage integration of investigative work on dispositional, biobehavioral, and developmental aspects of psychopathy with counterpart work on general psychopathology. Using the triarchic model of psychopathy as a frame of reference, I offer perspective on long-standing debates pertaining to the conceptualization and assessment of psychopathy, discuss how dispositional facets of psychopathy relate to subdimensions of internalizing and externalizing psychopathology, and summarize findings from contemporary biobehavioral and developmental research on psychopathy. I conclude by describing a systematic strategy for coordinating biobehavioral-developmental research on psychopathy that can enable it to be informed by, and help inform, ongoing research on mental health problems more broadly.
Predictors of uncertainty and unwillingness to receive the COVID-19 booster vaccine: An observational study of 22,139 fully vaccinated adults in the UK
Authors: Elise Paul, Daisy Fancourt
Journal: The Lancet Regional Health - Europe (2022)

The continued success of the COVID-19 vaccination programme in the UK will depend on widespread uptake of booster vaccines. However, there is evidence of hesitancy and unwillingness to receive the booster vaccine, even in fully vaccinated adults. Identifying factors associated with COVID-19 booster vaccine intentions specifically in this population is therefore critical. We used data from 22,139 fully vaccinated adults who took part in the UCL COVID-19 Social Study. Multinomial logistic regression examined predictors of uncertainty and unwillingness (versus willingness) to receive a COVID-19 booster vaccine (measured 22 November 2021 to 6 December 2021), including (i) socio-demographic factors, (ii) COVID-19 related factors (e.g., having been infected with COVID-19), and (iii) initial intent to receive a COVID-19 vaccine in the four months following the announcement in the UK that the vaccines had been approved (2 December 2020 to 31 March 2021). 4% of the sample reported that they were uncertain about receiving a COVID-19 booster vaccine, and a further 4% unwilling. Initial uncertainty and unwillingness to accept the first COVID-19 vaccine in 2020-21 were each associated with over five times the risk of being uncertain about and unwilling to accept a booster vaccine. Healthy adults (those without a pre-existing physical health condition) were also more likely to be uncertain or unwilling to receive a booster vaccine. In addition, low levels of current stress about catching or becoming seriously ill from COVID-19, consistently low compliance with COVID-19 government guidelines during periods of strict restrictions (e.g., lockdowns), lower levels of educational qualification, lower socio-economic position, and age below 45 years were all associated with uncertainty and unwillingness. Our findings highlight that there are a range of factors that predict booster intentions, with the strongest predictor being previous uncertainty and unwillingness. Two other concerning patterns also emerged from our results. First, administration of booster vaccinations may increase social inequalities in experiences of COVID-19 as adults from lower socio-economic backgrounds are also most likely to be uncertain or unwilling to accept a booster vaccine as well as most likely to be seriously affected by the virus. Second, some of those most likely to spread COVID-19 (i.e., those with poor compliance with guidelines) are most likely to be uncertain and unwilling. Public health messaging should be tailored specifically to these groups. The Nuffield Foundation [WEL/FR-000022583], the MARCH Mental Health Network funded by the Cross-Disciplinary Mental Health Network Plus initiative supported by UK Research and Innovation [ES/S002588/1], and the Wellcome Trust [221400/Z/20/Z and 205407/Z/16/Z].
Abstract 331: Loss of Myosin Binding Protein H-Like Causes Cardiac Conduction Abnormalities
Authors: David Y Barefield, Sean Yamakawa, Ibrahim Tahtah, Jordan J Sell, Michael Broman, Brigitte Laforest, Megan J Pickelwartz, Lisa D Wilsbacher, Andrew Wasserstrom, Glenn I Fishman, Elizabeth McNally
Journal: Circulation Research (2019)

A premature truncation (R255X) in MYBPHL associates with human dilated cardiomyopathy (DCM) and arrhythmias. Loss of Mybphl in mice causes DCM and arrhythmia. MYBPHL encodes myosin binding protein H-like (MyBP-HL) and is expressed highly in the atria. We hypothesize that MyBP-HL is required for proper conduction system function. Immunofluorescence microscopy on normal human atria showed MyBP-HL staining in all atrial cardiomyocytes with a sarcomere A-band pattern. Atria from the heterozygous (het) MYBPHL R255X mutant carrier lacked MyBP-HL staining. Human induced pluripotent stem cell-derived cardiomyocytes from the het MYBPHL R255X carrier and control cell lines were also examined. MyBP-HL was found in a subset of control cardiomyocytes, whereas R255X cells showed no MyBP-HL, suggesting that the R255X allele exerts a dominant-negative effect on the normal MYBPHL allele. Immunofluorescence microscopy in wild-type (WT) mouse ventricles identified MyBP-HL-positive ventricular cardiomyocytes that co-localized with the ventricular conduction system marker contactin-2 near the atrioventricular node and in a subset of Purkinje fibers. Mybphl het ventricles have 10% as many MyBP-HL-positive cells compared to WT. Surface telemetry revealed atrioventricular block and atrial bigeminy and intracardiac pacing revealed a shorter atrial relative refractory period and inducible atrial tachycardia in Mybphl -null mice. Ca 2+ transients measured with confocal microscopy revealed that isolated Mybphl -null atrial cardiomyocytes had an increased occurrence of triggered Ca 2+ waves and more heterogenous Ca 2+ release than WT controls. Super-resolution microscopy revealed ryanodine receptor disorganization in Mybphl het and null atrial cardiomyocytes compared to WT controls. Abnormal Ca 2+ release, shorter atrial refractory period, and dilated atria could account for the observed atrial arrhythmias, bigeminy, and atrial tachycardia.
ACCF/AHA/HRS/SCAI clinical competence statement on physician knowledge to optimize patient safety and image quality in fluoroscopically guided invasive cardiovascular procedures
Authors: John W. Hirshfeld, Stephen Balter, Jeffrey A. Brinker, Morton J. Kern, Lloyd W. Klein, Bruce D. Lindsay, Carl L. Tommaso, Cynthia M. Tracy, Louis K. Wagner, Mark A. Creager, Michael Elnicki, John W. Hirshfeld, Beverly H. Lorell, George P. Rodgers, Cynthia M. Tracy, Howard H. Weitz
Journal: Journal of the American College of Cardiology (2004)
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes
Authors: Yuchen Xie, Merve Sahin, Sonali Sinha, Yufeng Wang, Amrita M. Nargund, Yang Lyu, Song Han, Yiyu Dong, James J. Hsieh, Christina S. Leslie, Emily H. Cheng
Journal: Nature Cancer (2022)
A Text-book of the Practice of Medicine.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rheumatologists Issue Guidelines for Preventing and Treating Corticosteroid-lnduced Osteoporosis
Authors: Andrew A. Skolnick
Journal: JAMA (1997)

DESPITE ALL that is known about the bone-robbing effects of corticosteroids, many physicians still do not realize the importance of prescribing proper therapy to prevent osteoporosis in patients on long-term corticosteroid treatment. That is the finding of a study reported at the 1996 National Scientific Meeting of the American College of Rheumatology (ACR) in Orlando, Fla. The study found that the majority of physicians surveyed in 1995 underestimated the risk of osteoporosis from corticosteroid use in men and premenopausal women. Most also did not know about the efficacy of several leading therapies for preventing bone loss. To better educate physicians regarding the care of patients taking corticosteroids, the ACR released at the meeting its first guidelines for the medical management of steroid-induced osteoporosis. The guidelines describe the options the ACR recommends for women, men, and children who are taking corticosteroids (<i>Arthritis Rheum</i>. 1996;39: 1791-1801). Corticosteroids are widely used for treating
Adolescent tuberculosis
Authors: Kathryn J Snow, Andrea T Cruz, James A Seddon, Rashida A Ferrand, Silvia S Chiang, Jennifer A Hughes, Beate Kampmann, Steve M Graham, Peter J Dodd, Rein M Houben, Justin T Denholm, Susan M Sawyer, Katharina Kranzer
Journal: The Lancet Child & Adolescent Health (2019)
Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis
Authors: Ana Teresa Limon-Miro, Clive Douglas Jackson, Tannaz Eslamparast, Hisami Yamanaka-Okumura, Lindsay Dudley Plank, Christiani Jeyakumar Henry, Angela Mary Madden, Livia Garcia Ferreira, Evangelos Kalaitzakis, César Prieto de Frías, Anne Wilkens Knudsen, Leah Gramlich, Maitreyi Raman, Cathy Alberda, Dawn Belland, Vanessa Den Heyer, Puneeta Tandon, Marsha Yvonne Morgan
Journal: Journal of Hepatology (2022)
Two 'Firsts'
Authors: Phil Gunby
Journal: JAMA (1989)

READERS WILL see a new heading in this week's Medical News &amp; Perspectives section—From the Congressional Office of Technology Assessment. This is the first report of its kind in<i>JAMA</i>from this small but influential office, some functions of which are explained in the editorial on page 550. Also in this week's section, under a different heading (From the Assistant Secretary for Health), is an outline of health objectives for the closing years of this century.<i>JAMA</i>has carried these secretarial reports for more than a year and a half, but this is the first from the new assistant secretary, James O. Mason, MD, DrPH (<i>JAMA</i>. 1989;261: 3367).—by
Differential PTGDR2 Expression In Blood Cell Populations From Asthmatic Patients After Treatment With Anti-IL5 Or Anti-IL4R
Authors: Maria Martin, Miguel Estravis, Asuncion Garcia-Sanchez, Jaqueline Perez-Pazos, Cristina Martin-Garcia, Ignacio Davila, Catalina Sanz
Journal: Journal of Allergy and Clinical Immunology (2022)
Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Authors: Jerome Galon, Luciana Batista, Florence Marliot, Jacques Fieschi, Marc Van den Eynde, Franck Pagès, Fabienne Hermitte, Xiaoyi Chen, Amos Kirilovsky, Thomas Sbarrato, Carine El Sissy, Nacilla Haicheur-Adjouri, Maria-Gabriela Anitei, Ana-Maria Musina, Viorel Scripcariu, Christine Lagorce-Pagès
Journal: Journal for ImmunoTherapy of Cancer (2020)
Allergen-Induced Extracellular Release of Self-DNA Promotes Innate Type 2 Immune Responses in the Lung
Authors: Koji Iijima, Takao Kobayashi, Kenzo Ohara, Koji Matsumoto, Rinna Tei, Scott O'Grady, Hirohito Kita
Journal: Journal of Allergy and Clinical Immunology (2022)
CAR Mechanics: Driving T Cells into the MUC of Cancer
Authors: John Maher, Scott Wilkie
Journal: Cancer Research (2009)

Several monoclonal antibodies bind in a highly selective manner to tumor-associated glycoforms of MUC1. We set out to exploit this by developing a MUC1-specific chimeric antigen receptor. Difficulties were encountered in this endeavor, owing to MUC1-imposed steric hindrance and antigenic heterogeneity. These issues were addressed by the iterative engineering of all components of the fusion receptor. Our experience underlines the need for careful individual optimization of immunotherapeutic reagents as dictated by the molecular vagaries of the target under study.
Role of FDG PET/CT in the Evaluation of Therapy Response in Systemic Juvenile Xanthogranuloma
Authors: Mehmet Emin Mavi, Basak Soydas Turan, Bilge Volkan Salanci, Murat Fani Bozkurt
Journal: Clinical Nuclear Medicine (2022)

Abstract Juvenile xanthogranuloma, a rare type of non-Langerhans cell histiocytosis, is mostly seen in childhood and adolescence and generally manifests as widespread skin lesions. It rarely shows systemic involvement. Although the cutaneous form is often self-limited, systemic form is quite aggressive. Here we report the findings of FDG PET/CT scans during the course of cladribine therapy in a 6-year-old girl with systemic juvenile xanthogranuloma.
Encouraging news on temporary coverings for burn wounds
Authors: W. A. Check
Journal: JAMA (1980)

Successful temporary protection of burns by two very different materials was described at the recent meeting of the American College of Surgeons in Atlanta. One covering, human amniotic membrane, has been used for this purpose, although sparingly, since 1913. However, a group of physicians from Allentown, Pa, has now developed a way of collecting and storing the membrane that makes it much easier to use. The other substance, called Biobrane, is a newly developed semisynthetic membrane composed of nylon, Silastic, and a collagen derivative. The new processing method for human amnion was reported by Andrew B. Walker, MD, a pediatric surgeon, Tamar Earnest, MD, and Alan Schragger, MD. Amniotic membrane has been known for some years to have desirable permeability properties, keeping wounds from drying out and preventing exogenous bacterial infection. But the usual method of preparing it entailed stripping the membrane from the placenta immediately after delivery. This